Litoxetine

Litoxetine
Clinical data
ATC code	none;
Identifiers
	IUPAC name 4-(naphthalen-2-ylmethoxy)piperidine;
CAS Number	86811-09-8;
PubChem CID	65650;
ChemSpider	59087;
UNII	9980ST005G;
ChEMBL	ChEMBL471036;
CompTox Dashboard (EPA)	DTXSID30235828 ;
Chemical and physical data
Formula	C16H19NO
Molar mass	241.327 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C3CNCCC3OCc2cc1ccccc1cc2;

Litoxetine (SL 81-0385) is an antidepressant which was under clinical development for the treatment of depression in the early 1990s.^[1] It acts as a serotonin reuptake inhibitor and 5-HT₃ receptor antagonist. It has prominent antiemetic properties, and unlike the selective serotonin reuptake inhibitors (SSRIs), it was shown to have a negligible incidence of nausea and emesis.^[2] Development of litoxetine for medicinal use was apparently halted in the late 1990s.

References

^ Fairweather DB, Patat A, Rosenzweig P, Curson VH, Dunmore C, Dubruc C, Hindmarch I (August 1995). "The psychomotor and cognitive effects of litoxetine in young and middle aged volunteers". British Journal of Clinical Pharmacology. 40 (2): 119–25. doi:10.1111/j.1365-2125.1995.tb05767.x. PMC 1365170. PMID 8562293.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Angel I, Schoemaker H, Prouteau M, Garreau M, Langer SZ (March 1993). "Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties". European Journal of Pharmacology. 232 (2–3): 139–45. doi:10.1016/0014-2999(93)90767-C. PMID 8385615.